Phase I clinical experience interview with Pacylex CEO

Interview at the 2024 ASCO-GI conference, where our CEO shares the Phase 1 clinical experience with zelenirstat, our first in class, oral, cancer medicine in Phase 2. Take a look.  https://allen-oncologytu.cincopa.com/watch/A4HAcLOLOO68!A0FDSkoSP1Bh